Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

William Insull, Peter P. Toth, H. Robert Superko, Roopal B. Thakkar, Scott Krause, Ping Jiang, Rhea A. Parreno, Robert J. Padley

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Objective: To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia. Patients and methods: Patients (n = 137) with dyslipidemia (not previously receiving statin therapy or having discontinued any lipid-altering treatment 4-5 weeks prior to the study) received NER/S (1000/40 mg/day for four weeks, then 2000/40 mg/day for eight weeks) or atorvastatin 40 mg/day for 12 weeks. Median percent changes in apolipoprotein (apo) A-1, apo B, and the apo B:A-I ratio, and nuclear magnetic resonance lipoprotein subclasses from baseline to week 12 were compared using the Wilcoxon rank-sum test and Fisher's exact test. Results: NER/S treatment produced significantly greater percent changes in apo A-I and apo B:A-I, and, at the final visit, apo B < 80 mg/dL was attained by 59% versus 33% of patients, compared with atorvastatin treatment (P = 0.003). NER/S treatment resulted in greater percent reductions in calculated particle numbers for low-density lipoprotein (LDL, 52% versus 43%; P = 0.022), small LDL (55% versus 45%; P = 0.011), very low-density lipoprotein (VLDL) and total chylomicrons (63% versus 39%; P < 0.001), and greater increases in particle size for LDL (2.7% versus 1.0%; P = 0.007) and VLDL (9.3% versus 0.1%; P < 0.001), compared with atorvastatin. Conclusion: NER/S treatment significantly improved apo A-I levels and the apo B:A-I ratio, significantly lowered the number of atherogenic LDL particles and VLDL and chylomicron particles, and increased the mean size of LDL and VLDL particles, compared with atorvastatin.

Original languageEnglish (US)
Pages (from-to)1065-1075
Number of pages11
JournalVascular Health and Risk Management
Volume6
Issue number1
DOIs
StatePublished - 2010

Keywords

  • Atorvastatin
  • Diameter
  • Dyslipidemia
  • Lipid particles
  • Niacin
  • Number
  • Simvastatin
  • Size

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy'. Together they form a unique fingerprint.

Cite this